Synthetic Biologics Reports 2021 Year End Operational Highlights and Financial Results

-Completed acquisition of VCN Biosciences, expanding pipeline into oncology-

-VCN-01 received Orphan Drug Designation for retinoblastoma from the U.S. FDA-